Immix Biopharma(US:IMMX) Globenewswire·2026-03-30 12:45Core Insights - Immix Biopharma has completed enrollment for the NEXICART-2 trial, with topline results expected in Q3 2026, followed by a Biologics License Application (BLA) submission and planned commercial launch [1][2] - The company has appointed Richard Graydon, MD, PhD, as Chief Medical Officer, who has extensive experience in clinical development from Merck and Johnson & Johnson [2] - NXC-201, the lead candidate, is a CAR-T cell therapy targeting relapsed/refractory AL Amyloidosis and has received Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation from the FDA [6][8] Company Overview - Immix Biopharma, Inc. is a leader in the treatment of relapsed/refractory AL Amyloidosis, a disease characterized by the production of toxic light chains that lead to organ failure [7] - The company is focused on developing NXC-201, a CAR-T therapy designed to eliminate the source of toxic light chains [6][7] Clinical Trial Details - NEXICART-2 is a Phase 2 clinical trial involving 40 patients, designed to evaluate the efficacy of NXC-201 in treating relapsed/refractory AL Amyloidosis [3] - The trial has a registrational design, indicating its potential to support a BLA submission upon successful results [3] Market Insights - The AL Amyloidosis patient population in the U.S. is projected to grow at a rate of 12% annually, reaching approximately 38,500 patients by 2026 [4] - The market for AL Amyloidosis treatments was valued at $3.6 billion in 2017 and is expected to grow to $6 billion by 2025 [5]